Outcome and Prognostic Factors of Low-Grade Astrocytoma: Namazi Hospital, Shiraz, Iran (۲۰۰۶–۲۰۱۳)
- سال انتشار: 1402
- محل انتشار: مجله قانون طب، دوره: 4، شماره: 1
- کد COI اختصاصی: JR_CJM-4-1_001
- زبان مقاله: انگلیسی
- تعداد مشاهده: 128
نویسندگان
Department of Radiation oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Golestan University of Medical Sciences, Gorgan, Iran.
Breast Diseases Research Center, school of medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Radiation Oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Breast Diseases Research Center, school of medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Radiation oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Colorectal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Radiation oncology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Center for Collaborative Research, Orlando, Florida, USA.
چکیده
Introduction: Primary brain tumors, although not among the most common site of tumors, are considered an important pathology, due to their high mortality rate. Astrocytoma is a glial brain tumor with a high mortality rate. The predictors of the patients’ outcome is thus of great importance. In the present study, we investigated the results of ۷–year follow–up of patients with astrocytoma in order to determine the prognostic factors associated with patients’ survival. Methods: In this cross–sectional study, ۱۱۵ patients suffering from astrocytoma grade II, who referred to radio–oncology department of Nemazee hospital between ۲۰۰۶ and ۲۰۱۳, were included. The patients’ overall survival (OS) and disease–free survival (DFS) were recorded and their difference according to demographic and clinical characteristics of patients, as well as the treatment used, was evaluated using SPSS v.۲۵.Results: Mean age of patients was ۳۵.۳۴±۱۵.۱۷ years; most were younger than ۴۰ years old (۷۱%) and men (۵۹%). Mean OS and DFS were ۷۴.۹۰±۴۳.۰۵ and ۲۶.۶۱±۲۶.۹۷ months, respectively. Patients younger than ۴۰ had a significantly longer mean OS (۸۴.۰۴±۳۷.۹۳ vs. ۵۳.۰۴±۴۷.۴۱ months; P=۰.۰۰۴). Mean DFS was different according to chemotherapy and dose of radiotherapy (P=۰.۰۴۱ and ۰.۰۱, respectively), while OS was not (P> ۰.۰۵). Conclusion: Considering the difference in outcome of patients, specifically DFS, according to the performance of chemotherapy and the dose of radiotherapy, it is recommended to pay greater attention to appropriate choice of treatment strategy of patients with astrocytoma. Further randomized controlled studies are required to determine the predictors of patients’ outcome.کلیدواژه ها
Brain neoplasms, astrocytoma, radiotherapy, Chemotherapyاطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.